1
|
Langerhans cell histiocytosis.
|
Skeletal Radiol
|
2006
|
1.62
|
2
|
MicroRNA-199a-3p is downregulated in human osteosarcoma and regulates cell proliferation and migration.
|
Mol Cancer Ther
|
2011
|
1.51
|
3
|
Sacral chordomas: Impact of high-dose proton/photon-beam radiation therapy combined with or without surgery for primary versus recurrent tumor.
|
Int J Radiat Oncol Biol Phys
|
2006
|
1.50
|
4
|
Osteoblastoma: a 30-year study of 99 cases.
|
J Surg Oncol
|
2008
|
1.40
|
5
|
Osteoid osteoma and osteoblastoma.
|
J Am Acad Orthop Surg
|
2011
|
1.23
|
6
|
CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells.
|
Cancer Chemother Pharmacol
|
2008
|
1.23
|
7
|
Differential expression of microRNA (miRNA) in chordoma reveals a role for miRNA-1 in Met expression.
|
J Orthop Res
|
2010
|
1.16
|
8
|
Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma.
|
PLoS One
|
2010
|
1.16
|
9
|
A novel target for treatment of chordoma: signal transducers and activators of transcription 3.
|
Mol Cancer Ther
|
2009
|
1.07
|
10
|
Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer.
|
Clin Cancer Res
|
2010
|
1.06
|
11
|
Doxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug resistance in osteosarcoma.
|
BMC Cancer
|
2009
|
1.05
|
12
|
ROCK1 as a potential therapeutic target in osteosarcoma.
|
J Orthop Res
|
2011
|
1.04
|
13
|
Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines.
|
Mol Cancer Ther
|
2009
|
1.04
|
14
|
Activation of signal transducer and activator of transcription 3 (Stat3) pathway in osteosarcoma cells and overexpression of phosphorylated-Stat3 correlates with poor prognosis.
|
J Orthop Res
|
2010
|
1.03
|
15
|
Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells.
|
Cancer Chemother Pharmacol
|
2010
|
1.01
|
16
|
A validated disease severity scoring system for adults with type 1 Gaucher disease.
|
Genet Med
|
2010
|
1.01
|
17
|
The kinase Mirk is a potential therapeutic target in osteosarcoma.
|
Carcinogenesis
|
2009
|
1.01
|
18
|
Systematic kinome shRNA screening identifies CDK11 (PITSLRE) kinase expression is critical for osteosarcoma cell growth and proliferation.
|
Clin Cancer Res
|
2012
|
0.99
|
19
|
Combination of PI3K/mTOR inhibition demonstrates efficacy in human chordoma.
|
Anticancer Res
|
2009
|
0.97
|
20
|
Characterization and analysis of human chordoma cell lines.
|
Spine (Phila Pa 1976)
|
2010
|
0.97
|
21
|
Lentiviral shRNA screen of human kinases identifies PLK1 as a potential therapeutic target for osteosarcoma.
|
Cancer Lett
|
2010
|
0.97
|
22
|
Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy.
|
Blood Cells Mol Dis
|
2002
|
0.96
|
23
|
Tissue microarray immunohistochemical detection of brachyury is not a prognostic indicator in chordoma.
|
PLoS One
|
2013
|
0.95
|
24
|
Targeting hedgehog-GLI-2 pathway in osteosarcoma.
|
J Orthop Res
|
2012
|
0.92
|
25
|
Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells.
|
Cancer Lett
|
2013
|
0.89
|
26
|
Lentiviral short hairpin RNA screen of genes associated with multidrug resistance identifies PRP-4 as a new regulator of chemoresistance in human ovarian cancer.
|
Mol Cancer Ther
|
2008
|
0.89
|
27
|
Histone deacetylase inhibitor PCI-24781 enhances chemotherapy-induced apoptosis in multidrug-resistant sarcoma cell lines.
|
Anticancer Res
|
2011
|
0.88
|
28
|
Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
|
Anticancer Drugs
|
2011
|
0.87
|
29
|
Synthesis and evaluation of (2-(4-methoxyphenyl)-4-quinolinyl)(2-piperidinyl)methanol (NSC23925) isomers to reverse multidrug resistance in cancer.
|
J Med Chem
|
2012
|
0.87
|
30
|
Cyclin G-associated kinase is necessary for osteosarcoma cell proliferation and receptor trafficking.
|
Mol Cancer Ther
|
2010
|
0.87
|
31
|
Prognostic significance of miRNA-1 (miR-1) expression in patients with chordoma.
|
J Orthop Res
|
2014
|
0.86
|
32
|
Multidrug resistant osteosarcoma cell lines exhibit deficiency of GADD45alpha expression.
|
Apoptosis
|
2009
|
0.85
|
33
|
ZNF93 increases resistance to ET-743 (Trabectedin; Yondelis) and PM00104 (Zalypsis) in human cancer cell lines.
|
PLoS One
|
2009
|
0.83
|
34
|
Position statement: National Gaucher Foundation Medical Advisory Board, January 7, 2014.
|
Am J Hematol
|
2014
|
0.82
|
35
|
Blockage of Stat3 with CDDO-Me inhibits tumor cell growth in chordoma.
|
Spine (Phila Pa 1976)
|
2010
|
0.82
|
36
|
RAIDD expression is impaired in multidrug resistant osteosarcoma cell lines.
|
Cancer Chemother Pharmacol
|
2009
|
0.82
|
37
|
Multidrug resistance reversal agent, NSC77037, identified with a cell-based screening assay.
|
J Biomol Screen
|
2010
|
0.82
|
38
|
Prevalence of type 1 Gaucher disease in the United States.
|
Arch Intern Med
|
2008
|
0.81
|
39
|
Use of plain radiography to optimize skeletal outcomes in children with type 1 Gaucher disease in Brazil.
|
J Pediatr Orthop
|
2007
|
0.80
|
40
|
A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells.
|
BMC Cancer
|
2014
|
0.78
|
41
|
Sarcoidosis of the spine: a report of five cases and a review of the literature.
|
J Bone Joint Surg Am
|
2012
|
0.76
|
42
|
Development of a new pre-vascularized tissue-engineered construct using pre-differentiated rADSCs, arteriovenous vascular bundle and porous nano-hydroxyapatide-polyamide 66 scaffold.
|
BMC Musculoskelet Disord
|
2013
|
0.75
|